# NPPA caps cancer drug profit at 30%, prices may drop 70% 2026-10-17T18:51:46+00:00 | Governance | Indian Opinion Desk Corroboration: 1 independent outlet The National Pharmaceuticals Pricing Authority (NPPA) has capped the profit margin on 137 non-scheduled cancer drugs at 30%. The decision, published in a gazette notification on Saturday, 17 October 2026, takes effect from 9 November 2026. Retail prices of these life-saving drugs could fall by up to 70% from current levels. The government told the Supreme Court two days ago that the cap is expected to save patients about Rs 2,500 crore annually. The recommendation came from an expert committee under the Directorate General of Health Services (DGHS), comprising oncologists, medical experts, hospital specialists and government officials. The list will be updated periodically. State drug controllers have been directed to monitor compliance by manufacturers, dealers, retailers, hospitals and medical institutions. ## Indian Opinion Analysis The price cap directly targets the high out-of-pocket expenditure that cancer patients face, since many of these 137 drugs are not in the National List of Essential Medicines and therefore had no price control until now. What remains unresolved is how manufacturers will adjust: they may absorb the margin cut or exit unprofitable products. The Supreme Court, which heard the matter on 15 October, has asked the government to reply by 27 October on why similar price controls are not applied to other drugs, signalling that the cap on cancer drugs alone may not settle the broader pricing debate. ## Coverage - bhaskar.com Leads with NPPA notification and expected price drop, no editorial slant This brief was synthesised by AI from the source linked above. Tags: Cancer drugs, DGHS, NPPA, Supreme Court Canonical: https://indianopinion.org/nppa-caps-cancer-drug-profit-at-30-prices-may-drop-70/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/nppa-caps-cancer-drug-profit-at-30-prices-may-drop-70/#story-in-brief How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/